Your browser doesn't support javascript.
loading
Experiences of adults living with refractory epilepsy and their views and expectations on receiving results from whole genome sequencing.
Addona, Cynthia; Hurlimann, Thierry; Jaitovich-Groisman, Iris; Godard, Beatrice.
Afiliação
  • Addona C; Université de Montréal, PO Box 6128, Station Centre-ville, Montréal, QC H3C 3J7, Canada.
  • Hurlimann T; Université de Montréal, PO Box 6128, Station Centre-ville, Montréal, QC H3C 3J7, Canada.
  • Jaitovich-Groisman I; Research Institute of the McGill University Health Center, Canada.
  • Godard B; Université de Montréal, PO Box 6128, Station Centre-ville, Montréal, QC H3C 3J7, Canada. Electronic address: beatrice.godard@umontreal.ca.
Epilepsy Res ; 196: 107221, 2023 10.
Article em En | MEDLINE | ID: mdl-37696194
ABSTRACT

INTRODUCTION:

Researchers, clinicians and patients are turning to new innovations in research and clinical practice to further their knowledge in the genetic domain and improve diagnostics or treatment. However, with increased knowledge in genetics, societal issues may arise. Being conscious of these issues is crucial in order to implement standardized and efficient testing on a wider scale that is accessible to a greater number of individuals while simultaneously returning test results, including incidental findings, in a timely manner.

METHODS:

Within the framework of a genomics research project, we invited 20 participants who suffer from refractory epilepsy to provide insight on their personal experiences with epilepsy, as well as their thoughts on receiving Whole Genome Sequencing (WGS) results and with whom they would feel comfortable sharing these results with.

RESULTS:

All participants had their own unique experience with epilepsy, such as how they handled their diagnosis, their struggles following the diagnosis, the healthcare services they received, how they shared their diagnosis with others, and how they managed stigmatization from others. Most participants would be eager to know their WGS results, whether the results be related to epilepsy (n = 19), response to pharmaceutical drugs including AEDs (n = 16), comorbidities (n = 19) and incidental findings (n = 15).

CONCLUSION:

Our findings reinforce the need to improve access to genetic testing for epilepsy patients in clinical settings. Furthermore, while acquiring more genetic knowledge (i.e. WGS) about epilepsy can provide answers for the affected population, it also requires the simultaneous involvement of several medical disciplines, with greater emphasis on genetic and psychological counseling.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia Resistente a Medicamentos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia Resistente a Medicamentos Idioma: En Ano de publicação: 2023 Tipo de documento: Article